NEW YORK (GenomeWeb News) – Qiagen today said that it has settled all outstanding litigation with Life Technologies business Applied Biosystems regarding real-time thermal cyclers for research and molecular diagnostic applications.
Qiagen inherited the dispute when it acquired Sydney, Australia-based Corbett Life Science last year. Corbett makes the Rotor-Gene Real-Time PCR-Cyclers, which were the focus of an infringement suit filed by ABI in Germany. Corbett subsequently filed a declaratory judgment in California, and along with Itf Labortechnik, it also filed an intervention in opposition proceedings before the European Patent Office.
As part of the settlement, Corbett has licensed from ABI real-time PCR technology that relates to Corbett's real-time PCR instrumentation. The license covers all fields including research, applied fields, and human and animal in vitro diagnostics, said Qiagen.
"This Real-Time Thermal Cycler license agreement for all fields including human in vitro diagnostics expands our existing PCR intellectual property estate, which is truly unique in the industry," said Qiagen CEO Peer Schatz in a statement. "This addition extends our molecular testing solution portfolio and puts Qiagen in a position to offer sample and assay technology solutions spanning from sample to result."
Financial terms of the agreement, which fully resolve all pending disputes between the parties, were not disclosed.